In Q2 2023, Driehaus Capital held 202 positions worth $4.5B. They initiated 67 new positions and exited 102. Their largest holding was XENE ($183.3M). Portfolio value shrank -9.0% versus the prior quarter.
Frequently asked questions
What stocks did Driehaus Capital own in Q2 2023?
Driehaus Capital held 202 biotech stocks in their 13F portfolio in Q2 2023. Their top positions include XENE, CCJ, IBN, INSP, ELF. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Driehaus Capital's portfolio worth in Q2 2023?
Driehaus Capital's tracked biotech portfolio was worth $4.5B across 202 positions, with total assets under management of approximately $28B. Portfolio values are based on 13F filings with the SEC.
What did Driehaus Capital buy in Q2 2023?
Driehaus Capital initiated 67 new positions in Q2 2023, including ENVX, SSD, GKOS, FIVN, SMMT and 62 more. They also increased 90 existing positions.
What did Driehaus Capital sell in Q2 2023?
Driehaus Capital fully exited 102 positions in Q2 2023, including XPEL, WING, WCC, WNC, VTS and 97 more. They also trimmed 41 existing positions.
Is Driehaus Capital a biotech fund?
Growth-oriented investment firm founded by Richard Driehaus (d. 2021), now led by CEO Steve Weber. Michael Caldwell manages the healthcare/life sciences portfolio, applying growth-at-a-reasonable-price philosophy to biotech with a focus on companies with accelerating revenue growth and approaching commercial inflection points.
Want AI analysis, insider signals, and catalyst overlays for Driehaus Capital?
View latest Driehaus Capital portfolio →